Skip to main content
Erschienen in: CME 6/2020

17.06.2020 | Arterielle Hypertonie | CME Fortbildung

Update Hypertonie: Ab wann und wie behandeln?

verfasst von: Prof. Dr. med. Ulrich Kintscher

Erschienen in: CME | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die arterielle Hypertonie gilt heute immer noch als der bedeutendste Risikofaktor für kardiovaskuläre Erkrankungen und damit einhergehenden Behinderungen weltweit. Obwohl die Versorgung der Patienten*innen mit arterieller Hypertonie sich in den letzten Jahren verbessert hat, sind immer noch große Teile der Behandelten nicht adäquat behandelt und es liegt eine geringe Therapieadhärenz vor. Die Diagnose der arteriellen Hypertonie wird bei den meisten Patienten*innen weiterhin bei einem Praxisblutdruckwert von ≥140/90 mmHg gestellt. Ab diesem Blutdruckwert sollte auch die Behandlung begonnen werden. Bei der medikamentösen Behandlung gab es wichtige Änderungen. Zur Vereinfachung des Therapieschemas und einer damit einhergehenden Verbesserung der Therapieadhärenz, sollte die Arzneimitteltherapie mit einer Zweifachkombination begonnen werden. Diese Zweifachkombination sollte als Fixdosis- oder sogenannte Single-Pill-Kombination verordnet werden.
Literatur
1.
Zurück zum Zitat Collaborators GBDRF (2016) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1659-1724 Collaborators GBDRF (2016) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1659-1724
2.
Zurück zum Zitat Neuhauser HK, Adler C, Rosario AS et al. (2015) Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens 29:247-253 Neuhauser HK, Adler C, Rosario AS et al. (2015) Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens 29:247-253
3.
Zurück zum Zitat Collaboration NCDRF (2019) Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 394:639-651 Collaboration NCDRF (2019) Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 394:639-651
4.
Zurück zum Zitat Kotseva K, De Backer G, De Bacquer D et al. (2019) Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European journal of preventive cardiology 26:824-835 Kotseva K, De Backer G, De Bacquer D et al. (2019) Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European journal of preventive cardiology 26:824-835
5.
Zurück zum Zitat Williams B, Mancia G, Spiering W et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021-3104 Williams B, Mancia G, Spiering W et al. (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021-3104
6.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:1269-1324 Whelton PK, Carey RM, Aronow WS et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:1269-1324
7.
Zurück zum Zitat Lonn EM, Bosch J, Lopez-Jaramillo P et al. (2016) Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 374:2009-2020 Lonn EM, Bosch J, Lopez-Jaramillo P et al. (2016) Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 374:2009-2020
8.
Zurück zum Zitat Brunstrom M, Carlberg B (2018) Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med 178:28-36 Brunstrom M, Carlberg B (2018) Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med 178:28-36
9.
Zurück zum Zitat Wright JT, Jr., Williamson JD, Whelton PK et al. (2015) A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373:2103-2116 Wright JT, Jr., Williamson JD, Whelton PK et al. (2015) A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373:2103-2116
10.
Zurück zum Zitat Kjeldsen SE, Lund-Johansen P, Nilsson PM et al. (2016) Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension 67:808-812 Kjeldsen SE, Lund-Johansen P, Nilsson PM et al. (2016) Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension 67:808-812
11.
Zurück zum Zitat Naderi SH, Bestwick JP, Wald DS (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125:882-887 e881 Naderi SH, Bestwick JP, Wald DS (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125:882-887 e881
12.
Zurück zum Zitat Gupta P, Patel P, Strauch B et al. (2017) Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension 69:1113-1120 Gupta P, Patel P, Strauch B et al. (2017) Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension 69:1113-1120
13.
Zurück zum Zitat Poulter NR, Borghi C, Parati G et al. (2019) Medication adherence in hypertension. J Hypertens Poulter NR, Borghi C, Parati G et al. (2019) Medication adherence in hypertension. J Hypertens
14.
Zurück zum Zitat Gupta AK, Arshad S, Poulter NR (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55:399-407 Gupta AK, Arshad S, Poulter NR (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55:399-407
15.
Zurück zum Zitat Rea F, Corrao G, Merlino L et al. (2018) Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 39:3654-3661 Rea F, Corrao G, Merlino L et al. (2018) Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 39:3654-3661
16.
Zurück zum Zitat Williams B, Macdonald TM, Morant S et al. (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059-2068 Williams B, Macdonald TM, Morant S et al. (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059-2068
18.
Zurück zum Zitat Pedersen SA, Gaist D, Schmidt SaJ et al. (2018) Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 78:673-681 e679 Pedersen SA, Gaist D, Schmidt SaJ et al. (2018) Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 78:673-681 e679
19.
Zurück zum Zitat Pottegard A, Hallas J, Olesen M et al. (2017) Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 282:322-331 Pottegard A, Hallas J, Olesen M et al. (2017) Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 282:322-331
Metadaten
Titel
Update Hypertonie: Ab wann und wie behandeln?
verfasst von
Prof. Dr. med. Ulrich Kintscher
Publikationsdatum
17.06.2020
Verlag
Springer Medizin
Erschienen in
CME / Ausgabe 6/2020
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-020-7973-1

Weitere Artikel der Ausgabe 6/2020

CME 6/2020 Zur Ausgabe

Medizin

Medizin

Medizin

Medizin